Literature DB >> 22797415

Spirometric reference values for advanced age from a South german population.

Stefan Karrasch1, Claudia Flexeder, Jürgen Behr, Rolf Holle, Rudolf M Huber, Rudolf A Jörres, Dennis Nowak, Annette Peters, H-Erich Wichmann, Joachim Heinrich, Holger Schulz.   

Abstract

BACKGROUND: The diagnostic use of lung function using spirometry depends on the validity of reference equations. A multitude of spirometric prediction values have been published, but in most of these studies older age groups are underrepresented.
OBJECTIVES: The aim of the present study was to establish new spirometric reference values for advanced age and to compare these to recent prediction equations from population-based studies.
METHODS: In the present study spirometry was performed in a population-based sample from the KORA-F4 and KORA-Age cohorts (2006-2009, Augsburg, Germany) comprising 592 never-smoking subjects aged 42-89 years and with no history of respiratory disease. Using quantile regression analysis, equations for the median and lower limit of normal were derived for indices characterizing the expiratory flow-volume curve: forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), FEV1/FVC, peak expiratory flow (PEF), and forced expiratory flow rates at 25, 50 and 75% of exhaled FVC (FEF25, FEF50 and FEF75).
RESULTS: FEV1 and FVC were slightly higher, and PEF was lower compared to recently published equations. Importantly, forced expiratory flow rates at middle and low lung volume, as putative indicators of small airway disease, were in good agreement with recent data, especially for older age.
CONCLUSION: Our study provides up-to-date reference equations for all major indices of flow-volume curves in middle and advanced age in a South German population. The small deviations from published equations indicate that there might be some regional differences of lung function within the Caucasian population of advanced age in Europe.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2012        PMID: 22797415     DOI: 10.1159/000338780

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  11 in total

1.  Metastable DNA methylation sites associated with longitudinal lung function decline and aging in humans: an epigenome-wide study in the NAS and KORA cohorts.

Authors:  Juan Jose Carmona; Richard T Barfield; Tommaso Panni; Jamaji C Nwanaji-Enwerem; Allan C Just; John N Hutchinson; Elena Colicino; Stefan Karrasch; Simone Wahl; Sonja Kunze; Nadereh Jafari; Yinan Zheng; Lifang Hou; Dawn L DeMeo; Augusto A Litonjua; Pantel S Vokonas; Annette Peters; Xihong Lin; Joel Schwartz; Holger Schulz; Andrea A Baccarelli
Journal:  Epigenetics       Date:  2018-10-21       Impact factor: 4.528

2.  Heterogeneous pattern of differences in respiratory parameters between elderly with either good or poor FEV1.

Authors:  Stefan Karrasch; Jürgen Behr; Rudolf M Huber; Dennis Nowak; Annette Peters; Stefan Peters; Rolf Holle; Rudolf A Jörres; Holger Schulz
Journal:  BMC Pulm Med       Date:  2018-02-06       Impact factor: 3.317

3.  Association of lung function with overall mortality is independent of inflammatory, cardiac, and functional biomarkers in older adults: the ActiFE-study.

Authors:  Dhayana Dallmeier; Dietrich Rothenbacher; Gudrun Weinmayr; Holger Schulz; Jochen Klenk; Michael Denkinger; Enric Duran-Tauleria; Wolfgang Koenig
Journal:  Sci Rep       Date:  2020-07-17       Impact factor: 4.379

4.  Reference values of impulse oscillometric lung function indices in adults of advanced age.

Authors:  Holger Schulz; Claudia Flexeder; Jürgen Behr; Margit Heier; Rolf Holle; Rudolf M Huber; Rudolf A Jörres; Dennis Nowak; Annette Peters; H-Erich Wichmann; Joachim Heinrich; Stefan Karrasch
Journal:  PLoS One       Date:  2013-05-15       Impact factor: 3.240

Review 5.  Asthma in the elderly: a different disease?

Authors:  Salvatore Battaglia; Alida Benfante; Mario Spatafora; Nicola Scichilone
Journal:  Breathe (Sheff)       Date:  2016-03

6.  What is the impact of different spirometric criteria on the prevalence of spirometrically defined COPD and its comorbidities? Results from the population-based KORA study.

Authors:  Stefan Karrasch; Irene Brüske; Maia P Smith; Barbara Thorand; Cornelia Huth; Karl-Heinz Ladwig; Florian Kronenberg; Joachim Heinrich; Rolf Holle; Annette Peters; Holger Schulz
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-08-16

7.  Spirometric Reference Equations for Elderly Chinese in Jinan Aged 60-84 Years.

Authors:  Xin-Yu Tian; Chun-Hong Liu; De-Xiang Wang; Xiu-Li Ji; Hui Shi; Chun-Yan Zheng; Meng-Shuang Xie; Wei Xiao
Journal:  Chin Med J (Engl)       Date:  2018-05-05       Impact factor: 2.628

8.  Blood Immunoproteasome Activity Is Regulated by Sex, Age and in Chronic Inflammatory Diseases: A First Population-Based Study.

Authors:  Ilona Elisabeth Kammerl; Claudia Flexeder; Stefan Karrasch; Barbara Thorand; Margit Heier; Annette Peters; Holger Schulz; Silke Meiners
Journal:  Cells       Date:  2021-11-28       Impact factor: 6.600

9.  Metabolomics profiling reveals novel markers for leukocyte telomere length.

Authors:  Jonas Zierer; Gabi Kastenmüller; Karsten Suhre; Christian Gieger; Veryan Codd; Pei-Chien Tsai; Jordana Bell; Annette Peters; Konstantin Strauch; Holger Schulz; Stephan Weidinger; Robert P Mohney; Nilesh J Samani; Tim Spector; Massimo Mangino; Cristina Menni
Journal:  Aging (Albany NY)       Date:  2016-01       Impact factor: 5.682

10.  Accelerated epigenetic aging as a risk factor for chronic obstructive pulmonary disease and decreased lung function in two prospective cohort studies.

Authors:  Miyuki Breen; Jamaji C Nwanaji-Enwerem; Stefan Karrasch; Claudia Flexeder; Holger Schulz; Melanie Waldenberger; Sonja Kunze; Markus Ollert; Stefan Weidinger; Elena Colicino; Xu Gao; Cuicui Wang; Jincheng Shen; Allan C Just; Pantel Vokonas; David Sparrow; Lifang Hou; Joel D Schwartz; Andrea A Baccarelli; Annette Peters; Cavin K Ward-Caviness
Journal:  Aging (Albany NY)       Date:  2020-08-03       Impact factor: 5.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.